Anti-angiogenic effects of thalidomide: Expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta

Histochemistry and Cell Biology

Volumn 122, Issue 1, 2004, Pages 27-33

  Fujita, Keiko ^a   Asami, Yoshiko ^a   Tanaka, Kayoko ^a   Akita, Masumi ^a   Merker, Hans Joachim ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Angiogenesis; Apoptosis; Caspase 3; Cytochrome P 450; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; CASPASE 3; CYTOCHROME P450; THALIDOMIDE;

ANGIOGENESIS; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MICROTUBULE; MORPHOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

EID: 4043113512     PISSN: 09486143     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00418-004-0669-x     Document Type: Article

References (24)

1. Akita M, Murata E, Kaneko K, Ghaida J, Merker H-J (1993) Cell shape and arrangement of cultured aortic smooth muscle cells grown on collagen gels. Cell Tissue Res 274:91-95
2. Akita M, Murata E, Merker H-J, Kaneko K (1997a) Formation of new capillary-like tubes in a three-dimensional in vitro model (aorta/collagen gel). Ann Anat 179:127-136
3. Akita M, Murata E, Merker H-J, Kaneko K (1997b) Morphology of capillary-like structures in a three-dimensional aorta/collagen gel culture. Ann Anat 179:137-147
4. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J (1996) Human ICE/CED-3 protease nomenclature. Cell 87:171
5. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834
6. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendy NF, Wheatley DN (1999) An in vitro model of angiogenesis: basic features. Angiogenesis 3:335-344
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085
8. Diggle GE (2001) Thalidomide: 40 years on. Int J Clin Pract 55:627-631
9. Dredge K, Marriott JB, Macdonald CD, Man H-W, Chen R, Muller GW, Stirling D, Dalgleish AG (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166-1172
10. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 181:182-186
11. Fujita K, Asami Y, Murata E, Akita M, Kaneko K (2002) Effects of thalidomide, cytochrome P-450 and TNF-αon angiogenesis in a three-dimensional collagen gel-culture. Okajimas Folia Anat Jpn 79:101-106
12. Han DC, Lee MY, Shin KD, Jeon SB, Kim JM, Son KH, Kim HC, Kim HM, Kwon BM (2004) 2′-benzoyloxycinnamaldehyde induces apoptosis in human carcinoma via reactive oxygen species. J Biol Chem (279:6911-6920). [Epub ahead of print]
13. Lin HL, Liu TY, Wu CW, Chi CW (2001) 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G (2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 92:500-509
14. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525-4530
15. Nau H (1986) Species differences in pharmacokinetics and drug teratogenesis. Environ Health Perspect 70:113-129
16. Neubert R, Merker H-J, Neubert D (1995) Developmental model for thalidomide action. Nature 400:1500-1502
17. Parman T, Wiley MJ, Wells PG (1999) Free radical-medicated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585
18. Rajkumar SV (2001) Thalidomide in the treatment of multiple myeloma. Expert Rev Anticancer Ther 1:2-28
19. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6:3111-3116
20. Sauer H, Guenther J, Hescheler J, Wartenberg M (2000) Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am J Pathol 156:151-158
21. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
22. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87:503-508
23. Vesela D, Vesely D, Jelinek R (1994) Embryotoxicity in chick embryo of thalidomide hydrolysis products following metabolic activation by rat liver homogenate. Funct Dev Morphol 4:313-316
24. Wells PG, Kim PM, Laposa RR, Nicol CJ, Parman T, Winn L (1997) Oxidative damage in chemical teratogenesis. Mutat Res 396:65-78